| NCT ID | NCT05210114 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Enrico Novelli |
| Condition | Sickle Cell Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2022-01-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2022-01-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will validate the diagnostic accuracy of a cutaneous hydration sensor. This sensor will also be evaluated for its feasibility as a point-of-care device for the assessment of hydration status and its potential to guide hydration therapy in patients with sickle cell disease (SCD).
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Sickle Cell Disease (genotypes SS, SC, Sß-thalassemia, SD, SOArab) * Participants must be ≥12-years old * Participants that provide legally effective consent to all study procedures Exclusion Criteria: * Participants under 12-years old * Participants being treated with experimental therapies in clinical trials
Contact & Investigator
Enrico Novelli, MD
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT05210114 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05210114 currently recruiting?
Yes, NCT05210114 is actively recruiting participants. Contact the research team at noveex@upmc.edu for enrollment information.
Where is the NCT05210114 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT05210114 clinical trial?
NCT05210114 is sponsored by Enrico Novelli. The principal investigator is Enrico Novelli, MD at University of Pittsburgh. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.